2020 BATCH PHASE-II- CLINICAL POSTING & THEORY CLASS SCHEDULE Government Medical College MANJERI DATE 8 AM - 9 AM 11 AM - 12 NOON 1 PM- 2 PM 3 - 4 PM DAY 9 AM -10 AM 10 AM - 11 AM 12 PM - 1 PM 2 PM- 3 PM Introduction to Pathology Basics of Forensic Medicine (F.M.1.1) L PA 1.1 (L) 01-04-2022 FRI Introduction - General Surgery Introduction - General Introduction to Medicine (L) AETCOM (L) 02-04-2022 SAT AETCOM SGD Module 2.1: The C.M. 1.1 Define and describe the concept of public healt 03-04-2022 SUN 8 TO 9 10 -to 11 11 to 12 12 to 1 PM PA 1- Introduction to pathology (L) harmacotherapeutics PH1. 04-04-2022 MON CLINICAL POSTING PA 2.1 - (L) Demonstrate PA 2.6 (L) -Describe and Introduction to Microbiology the knowledge of the discuss cellular MI 1.1 L causes, mechanisms, types adaptations: atrophy, Morphology of bacteria 05-04-2022 TUE and effects of cell injury hypertrophy, MI 1.1 L and their clinical hyperplasia, metaplasia, CLINICAL POSTING significance(core) dysplasia(core) 11-1pm Overview of Bacterial infections & Taxonomy numerate and identify dru formulations and drug MI 1.1 L 06-04-2022 WED CLINICAL POSTING BACTERIAL GENETICS PA 2.2 -(L)- Describe the C.M. 1.1 Define and describe the concept of public health etiology of cell injury 07-04-2022 THU MI 1.1 L Distinguish between reversible & irreversible CLINICAL POSTING injury PA 2.4 -(L)Describe and unch break distribution, metabolism & excretion of drugs PH1.4 (L) 08-04-2022 FRI discuss cell death – types. FM1.1 (LECTURE)-BASICS OF FORENSIC MEDICINE CLINICAL POSTING mechanisms, necrosis, OG 2.1 -ANATOMY OF THE CM 1.2 Define Health; describe the holistic health U1.1, 1.2. Homeostasis & Febrile response and lunch break ncluding concept of spiritual health & the relativeness nediators of metabolic nfluence of host immune FEMALE REPRODUCTIVE AETCOM Module 2.1 09-04-2022 SAT & determinants of health. esponse, metabolic response status, risk factors and TRACT(L) Foundation of communication (2 SGD) omorbidities on the ebrile response IM 4.1 8 TO 9 10 -to 11 11 to 12 12 to 1 PM 10-04-2022 SUN CLINICAL POSTING PA 2.3 SGD - storage disorders 11-04-2022 MON PA 2.5 & 2.7 (L)-Describe and discuss pathologic Microscopy & Physiology of Microscopy calcifications and gangrene(core) PA 2.7 Describe bacteria Practicals 12-04-2022 TUE MI 1.1 and REFLECTION and discuss the mechanisms of cellular aging and SGD apoptosis (NON CORE) MI 1.1 CLINICAL POSTING

13-04-2022	WED	CLINICAL POSTING			ANTIMICROBIALS Agents, AMR MI 1.6 L	ABST Monitoring of AM therapy AMS MI 1.6 L		Describe absorption, distribution, metabolism & excretion of drugs PH1.4 (SGD)	Describe absorption, distribution, metabolism & excretion of drugs PH1.4 (SGD)
14-04-2022	THU				FORMATIVE ASSESSMENT	Describe general principles of mechanism of drug action PH1.5 (SGD)		PA 3 -{L}- Describe the pathogenesis and pathology of amyloidosis(core)	
15-04-2022	FRI	CLINICAL POSTING			PA 4.1 (L) Define & describe the general features of acute and chronic inflammation including stimuli, vascular	lunch break		Identify and describe the management of drug interactions PH1.8 (SGD)	FM 1.2 (SDL)- HISTORY OF FORENSIC MEDICINE
16-04-2022	SAT	FM 1.2,1.4 (L)- COURTS AND LEGAL PROCEDURES		Acute coronary syndromes- types&complications IM 2.5&IM 2.19		lunch break		Module 2.1 foundation of communication -1 SGD and 1 skill lab session	SPORTS
17-04-2022	SUN	8 TO 9		10 -to 11	11 to 12	12 to 1 PM	1-2 PM		3-Apr
18-04-2022	MON	CLINICAL POSTING			Describe nomenclature of drugs i.e. generic, branded drugs PH1.9 (L)	Defne,identify,describe management of ADR PH1.7 (L)	1 - 2	PA 4.1- (SGD)Define & describe events(core)	e the general features of acute and chronic inflammation including stimuli, vascular and cellular
19-04-2022	TUE	CLINICAL POSTING			PA 4.2 - SGD Enumerate and acute inflammation (core)			Culture Media & Methods SGD MI 1.1	Culture Media & Methods Practicals MI 1.1
20-04-2022	WED	CLINICAL POSTING			Sterilisation & Disinfection MI 1.4 L	Sterilisation & Disinfection SGD MI 1.4, 1.5		Describe principles of Pharmacovigilance & ADR reporting systems PH1.6 (SGD)	Describe principles of Pharmacovigilance & ADR reporting systems PH1.6 (SGD)
21-04-2022	THU	CLINICAL POSTING			Identification of Bacteria Conventional & Automated SGD MI 1.1	Calculate the dosage of drugs for an individual patient, child elderly and patient with renal dysfunctionPH1.12 (SGD)		PA 5.1 (L)Define and describe the process of repair and regeneration including wound healing and its types (core)	CM 1.3 Describe the characteristics of Agent, Host and Environmental factorsin health and disease and mutifactorial etiology of disease.
22-04-2022	FRI	CLINICAL POSTING CLINICAL POSTING			PA 5.1 (L)-Define and describe the process of repair and regeneration	lunch break		Calculate the dosage of drugs for an individual patient, child elderly and patient with renal	FM 1.5,1.6,1.7 (L)- COURTS AND LEGAL PROCEDURES
23-04-2022	SAT	C.M 1.7 Health indicators (L)	SU1.3 basic concepts of perioperative care L	Pathophysiology, manifestations of inflammatory and	OG 1.3 STILL BIRTH, ABORTION, OG 9.1 ABORTIONS(L)		Module 2.1 (L)	aetcom Module 2.2 Foundations of bioethics (L)	SPORTS
24-04-2022	SUN	8 TO 9		10 -to 11	11 to 12	12 to 1 PM	1-2 PM		3-Apr
25-04-2022	MON	CLINICAL POSTING	Describe MOA, types, ADRs, indications & contraindications of adrenergic & anti- adrenergic drugs PH1.13 (L)	Describe MOA, types, ADRs, indications & contraindications of adrenergic & anti- adrenergic drugs PH1.13	1 - 2	PA 6.1(L) Define and describe edema, its types, pathogenesis and clinical correlations(core)	PA 6.2 ,6.6 (L) Define and describe hyperemia, congestion , haemorrhage PA 6.6 Define and describe ischaemia/ infarction, its types, etiology, morphologic changes and clinical effects(core)		

26-04-2022	TUE	CLINICAL POSTING			PA 6.3 (L)Define and describe shock, its pathogenesis and its stages (core)	PA 6.4 (L)Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis		GRAM STAINING MI 1.2 PRACTICALS	Morphology, Cell wall theory Bacterial growth curve L forms MI 1.1 P
27-04-2022	WED	CLINICAL POSTING			Specimen collecti SGD & Pri MI 8.9 , N	acticals		Describe MOA, types, ADRs, indications & contraindications of adrenergic & anti-adrenergic drugs PH1.13 (SGD)	Describe MOA, types, ADRs, indications and contraindications of cholinergic & anticholinergic drugs PH1.14 (L)
28-04-2022	THU	CUNICAL POSTING	Normal Microbial Flora of Human body 1L	Describe MOA, type, ADRs, indications & contraindications of skeletal muscle relaxants PH1.15(L) - Integrated			CM1.4 Describe and discuss the natural history of diseaseC.M 1.5 Describe the application of interventions at various levels of prevention (SGD)(using appropriate case scenario)		
29-04-2022	FRI	CLINICAL POSTING CLINICAL POSTING			PA7.1 (L) Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and			indications and contraindications of cholinergic & anticholinergic drugs PH1.14 (L)	FM 1.8 (SDL)- LATEST DECISIONS/NOTIFICATION,RESOLUTION,CIRCULRAS,STANDING ORDERS RELATED TO M-L PRACTICE
30-04-2022	SAT	FM1.8(SDL)-LATEST DECISIONS/ NOTIFICATION, RESOLUTION, CIRCULARS, STANDING ORDERS RELATED TO M-L PRACTICE	SU2.1, 2.2. shock: types and principles of resuscitation. shock: management	Pathophysiology, manifestations of sepsis syndrome IM 4.7	OG 3.1 PHYSIOLOGY OF CONCEPTION ,DIAGNOSIS OF PREGNANCY(OG 6.1)(L)	lunch break	Module 2.3 SGD	aetcom Health care as aright SDL and SGD	SPORTS
01-05-2022	SUN	8 TO 9		10 -to 11	11 to 12	12 to 1 PM			
02-05-2022	MON	CLINICAL POSTING			Describe MOA, types, ADRs, indications and contraindications of cholinergic & anticholinergic drugs PH1.	Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local	1 - 2	6 -SGD -EMBOLISM	PA 11.1- SGD GENETICS
03-05-2022	TUE				PA7.2 (L) Describe the molec (core)			Sterilisation & Disinfection Visit to CSSD MI 1.5 (P)	Sterilisation & Disinfection Visit to CSSD SGD & REFLECTION
04-05-2022	WED	CLINICAL POSTING			VIRAL INFECTION An overview General Virology MI 1.1 (L) & lab diagnosis1. 1 L	FUNGAL INFECTIONS An overview General Mycology Lab diagnosis MI 1.1 (L)		PH1.15 Skeletal muscle relaxants (L)	PH1.15 Skeletal muscle relaxants (SGD)
05-05-2022	THU	CLINICAL POSTING			FORMATIVE ASSESSMENT AND REFLECTION	lunch break		Principles of chemotherapy PH1.42(L)	FM 1.9(SGD)-MEDICO- LEGAL CERTIFICATION
06-05-2022		CM 1.6 Describe and discuss the concepts principles of health promotion and education ,IEC and behavioural change communication	SU 3.1,3.2 Blood and blood products. Blood transfusions - Indications & complications	Describe clinical epidemiology and inherited and modifiable risk factors for common malignancies in India IM	OG 4.1 DEVELOPMENT OF FETUS AND PLACENTA(L)	lunch break	aetcom Module 2 Working in a heal	.4 th care team 2SGD	SPORTS

07-05-2022	SAT								
08-05-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM			
09-05-2022	MON	CLINICAL POSTING	191010	10-1011	Describe and discuss the rational use of antimicrobials including antibiotic stewardship program PH1.43 (L)	Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences)	1 - 2	PA 7.3 -SGD CHEMICAL AND VIRAL CARCINOGENESIS	PA7.4 (SGD) Describe the effects of tumor on the host including paraneoplastic syndrome (core)
10-05-2022	TUE	CLINICAL POSTING			PA 7.5 (L) Describe immunology and the immune response to cancer	PA 10.1 & 10.2 (L) Define and describe the		SGD on sources of infe	Categorise the infections(given) as Bacterial / Viral ction, route of transmission, preventive measures, essential Infection control practices (HH)
11-05-2022	WED	CLINICAL POSTING			PARASITIC INFECTIONS An overview General Parasitology 1L	Epidemiology of Infections Outbreaks MI 1.3 (L)		Describe the ratonal use of antimicrobials PH1.43(SGD) - Integrated (Microbiology)	Describe antibiotic stewardship programe PH1.43(SGD) - Integrated (Microbiology)
12-05-2022	THU				ANTIGEN SDL MI 1.8	Describe MOA,uses,a/e of protien synthesis inhibitors PH1.42(L)		PA 10.3 (L) Define and describe the pathogenesis and pathology of leprosy (core)	CM 1.8 Demographic profile India
13-05-2022	FRI	CLINICAL POSTING CLINICAL POSTING			FORMATIVE ASSESSMENT	lunch break		Describe MDR,XDR TB&drugs acting PH1.45(L) - Integrated (Microbiology, Respiratory Medicine)	FM2.1,2.2, 2.3(LECTURE/ AUTOPSY DEMONSTRATION)- THANATOLOGY 1
14-05-2022	SAT	FM 2.4,2.5,2.6 (L/AUTOPSY) - THANATOLOGY 2		clinical lecture	PA 11.2 (L) GENETICS Describe the pathogenesis and pathology of tumor and tumour like conditions in infancy and childhood (non		aetcom Module	2.4 Working in a health care tea	SPORTS
15-05-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM			
16-05-2022	MON	CLINICAL POSTING			Describe MOA,uses,a/e of protien synthesis inhibitors PH1.42(L)	Describe MOA,uses, A/E,dose of antimalarials,kala azar PH1.47(L) - Integrated (General Medicine)	1 - 2		efine and describe the pathogenesis and pathology of common bacterial, viral, protozoal and iseases (non core) #integrated with CM 8.1 (Linker)
17-05-2022	TUE				PA 8.1 (L) Describe the diagnostic role of cytology & its applications in clinical care(core)	PA 8.2 (L) Describe the basis of exfoliative cytology including the technique & stain used (core			Demonstration of Parsites of Human importance Gross/ Microscopy/ Pictures/ charts MI 1.2 (P)
18-05-2022	WED	CLINICAL POSTING			IMMUNO Innate & Acquired immur hea	nological mechanisms in		Describe the MOA,uses,A/E of cellwall synthesis inhibitors PH1.42 (L)	Describe the MOA,uses,A/E of cellwall synthesis inhibitors PH1.42 (L)
		CLINICAL POSTING							

19-05-2022	THU				Antigen & Antibody MI 1.8 (L)	Describe MOA, uses,A/E, dose of suphonamides & quinolones PH1.42(L)		principles and mechanisms involved in immunity (core)	M5.3Define and describe common Nutrition related health disorders(including macronutrient, PEM Micro Iron, iron Iodine zinc ,Vitamin A) d management(2 hrs)SGD+ linker + vertical intergrat,allignment)	
20-05-2022	FRI	CLINICAL POSTING CLINICAL POSTING			PA 9.2 (L) Describe the mechanism of Hypersensitivity reactions (core) INTEGRATED	lunch break		Describe the MOA,uses,A/E of antivirals & HIV drugs PH1. 48(L) - Integrated (Mcrobiology)	FM2.7,2.8,2.9 (L/AUTOPSY) - THANATOLOGY 3	
21-05-2022	SAT	CM 5.8 Describe and discuss the importance and methods of food	fc HOLIDAY	Describe the pathophysiolo	OG5.1 PRE EXISTING MED DI				SPORTS	
22-05-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM				
23-05-2022	MON	CLINICAL POSTING			Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in malaria PH1.	PH1.48 drugs used in UTI/ STD (SGD)	1 - 2	PA 9.3 (L) Describe the HLA System and the immune principles involved in transplant and the mechanism of transplant	PA 9.6 - SGD Define and describe the pathogenesis and pathology of HIV and AIDS (core)	
24-05-2022	TUE	CLINICAL POSTING CLINICAL POSTING			PA 9.4 (L) Define Autoimmunity. Enumerate Autoimmune disorders (Core)	PA 9.7 (L) Define and describe the pathogenesis of other common autoimmune diseases(Non core)		Demonstration and Practicals Fungal agents KOH, Gramstain, SDA culture, LPCB mount. India Ink MI 1.1, 1.2		
25-05-2022	WED	CLINICAL POSTING			Complement MI 1.8 1L	Immune response Cell mediated Antibody mediated 1L		Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in KALA AZAR, amebiasis and intestinal helminthiasis PH1.47 (SGD)	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in KALA AZAR, amebiasis and intestinal helminthiasis PH1.47 (SGD)	
26-05-2022	THU	CLINICAL POSTING			Immunoprophylaxis 1L	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in viral		PA 12.1 (SGD) Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol (core)	CM 5.5 Describe methods of nutritional surveillance ,principles of nutritional education and bilitation in context of socio cultural factors CM 5.6Enumerate and discuss the national nutrition policy,important national nutritional programmes including ICDS	
27-05-2022	FRI	CLINICAL POSTING			12.2 &12.3 (L) Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation (core)	lunch break		Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in viral diseases	FM 2.10 (SGD-AUTOPSY DEMONSTRATION)- ESTIMATION OF TIME SINCE DEATH	
28-05-2022	SAT	FM2.11, 2.12,2.13 (L& SGD-AUTOPSY DEMONSTRATION	N SU 5.1,5.2, 5.3, 5.5. Wound healing: Normal, abnormal healing. Managenet of wound.		OG 5.2 MATERNAL HR FACTORS & IMMUNIZATION STATUS(L)	lunch break		aetcom Module 2.4 th care team (2 hospital visit - g along session)	SPORTS	
29-05-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM				
30-05-2022	MON	CLINICAL POSTING	Antitubercular dugs PH1.44, 1.45 (L)	Antitubercular dugs PH1. 44, 1.45 (L)	1 - 2	PA 13.1 & PA 13.2 (L) Describe hematopoiesis and extramedullary hematopoiesis PA 13.2 Describe the role of	PA 13.3& 13.4 (L) Define and classify anemias 13.4 Enumerate and describe the investigations of anemia			

31-05-2022	TUE	CLINICAL POSTING			PA 14-(SGD) MHA	PA 15- (SGD) MEGALOBLASTIC ANEMIA			Antigen Antibody Reaction MI 1.8. 8.15 (P) Agglutination - Slide & tube Precipitation ELISA, Rapid tests (Immunochromatography) Mostarphidt National Health Programmes including Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar,
01-06-2022	WED	CLINICAL POSTING			Integrated teaching Transplant & Cancer Immuno deficiency disorders (Pathology)	HAI, Standard and Transmission based precautions & BMW 8.5-8.8, 1.4,1.5,1.6 1L		National Health Programmes including Tuberulosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Non- communicable disease, cancer PH1.55 (SGD) INTEGRATED WITH CM	National Health Programmes including Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Non-communicable disease, cancer PH1.55 (SGD) INTEGRATED WITH CM
02-06-2022	THU	CLINICAL POSTING		HAI, NSI, AMS & BMW 8.5-8.8, 1.4,1.5,1.6 (1L)	Antileprotic drugs PH1. 46 (L)		PA 17 - (SGD) APLASTIC ANEMIA	C.M 3.1 Describe the health hazards of air, water, noise and radiation pollution(2hrs)	
03-06-2022	FRI	CLINICAL POSTING CLINICAL POSTING			PA 16.1 & 16.2 (SGD) Define and classify hemolytic anemia (core)	lunch break		Describe the mechanisms of action, types, doses, side effects of antihypertensive drugs diuretics PH1.27(L) - Integrated (General	UTOPSY DEMONSTRATION - PRESERVATION OF VISCERA FOR CHEMICAL ANALYSIS AND POST MOR
04-06-2022	SAT	CM 17.1 Define and Describe the concept of health care of community CM 17.5 Describe health care delivery of India		Hypertension-etiology, pathophysiology&classific		lunch break	Forn	mative assessment	SPORTS
				ation IM 8.1-8.5					
05-06-2022	SUN	8 TO 9	9 to 10	ation IM 8.1-8.5	11 to 12	12 to 1 PM			
05-06-2022		8 TO 9 CLINICAL POSTING			11 to 12 Describe classification, MOA, types, doses, side effects of antihypertensivesPH1.27(L) - Integrated (General	Describe classification, MOA,types, doses, side effects of	1 - 2	PA 16.3 - (L)Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and	PA 16.4- (L) Describe the etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia. Describe briefly about PNH and Autoimmune hemolytic anemia.(CORE) PA 16.7 - Describe the correct technique to perform a cross match – coombs' test (CORE)
	MON	CLINICAL POSTING			Describe classification, MOA, types, doses, side effects of antihypertensivesPH1.27(L)	Describe classification, MOA,types, doses, side effects of antihypertensivesPH1.27 (L)- Integrated (General	-	pathogenesis, features, hematologic indices and peripheral blood picture of	picture of Acquired hemolytic anemia. Describe briefly about PNH and Autoimmune hemolytic anemia.(CORE) PA 16.7 - Describe the correct technique to perform a cross match – coombs'
06-06-2022	MON				Describe classification, MOA, types, doses, side effects of antihypertensivesPH1.27(L) - Integrated (General PA 18.1 - (L) NON NEO WBC Enumerate and describe the causes of leucocytosis leucopenia lymphocytosis	Describe classification, MOA,types, doses, side effects of antihypertensivesPH1.27 (L)- Integrated (General 16-SGD HEMOLYTIC	-	pathogenesis, features, hematologic indices and peripheral blood picture of	picture of Acquired hemolytic anemia. Describe briefly about PNH and Autoimmune hemolytic anemia.(CORE) PA 16.7 - Describe the correct technique to perform a cross match – coombs' test (CORE) Integrated teaching (2L)

09-06-2022	THU	CLINICAL POSTING			L & SDL Leprosy and other bacterial Skin and soft tissue infections PA 18.2 - (L) LEUKEMIA Describe the etiology,	Antifungal drugs PH1.42 (L)		PA 18.2 -(L) LEUKEMIA Describe the etiology, genetics, pathogenesis classification, features, hematologic features of acute and chronic leukemia INTEGRATED Anticancer drugs PH1.49(L)	be and enumerate principles, concepts and uses CM 7.5 Enumerate ,define ,describe and discuss epidemiological study designs FM2.17 (SGD) - EXHUMATION	
10-06-2022	FRI	CLINICAL POSTING								
11-06-2022	SAT	FM2.26 (SDL)-PM FINDINGS OF STARVATION AND NEGLET		Common cancers- genetics, risk factors, clinical presentations IM 13.1-13.4		lunch break			SPORTS	
12-06-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM				
13-06-2022	MON	8 TO 9 9 to 10 10-to 11 CLINICAL POSTING			Hypolipidemics PH1.30(L) - Integrated (General Medicine)		1 - 2	PA 19.1 (SGD) Enumerate the causes and describe differentiating features of Lymphadenopathy	PA 19.2 (SGD) Describe the pathogenesis and pathology of Tuberculous Lymphadenitis	
14-06-2022	TUE	CENTERED STATE			PA 19.4 (L) Describe and pathology and the different NH	iating features of HL and		PRACTICALS, DOAP - SKILLS LAB HAI, NSI, AMS & BMW 8.5-8.8, 1.4.1.5,1.6 P		
15-06-2022	WED	CLINICAL POSTING			L & S Viral Exanthems and other of MI 4.3,	cutaneous Viral infections		Describe drugs used in bronchial asthma,COPD PH1. 32(L) - Integrated (Respiratory Medicine)	Describe drugs used in bronchial sthma, COPD PH1.32(L) - Integrated (Respiratory Medicine)	
16-06-2022	THU	CLINICAL POSTING CLINICAL POSTING		FORMATIVE ASSESSMENT	FORMATIVE ASSESSMENT		FORMATIVE ASESSMENT	HOLIDAY		
17-06-2022	FRI	CLINICAL POSTING CLINICAL POSTING			PA 19.6 -(L) SPLENOMEGALY	lunch break		Describe Pharmacotherapy of cough PH1.33(SDL)	FM2.20, 2.21 (L) - AUTOPSY DEMONSTARTION- MECHANICAL ASPHYXIA	
18-06-2022	SAT	Anemia definition,causes, of patient with occupational illness including agriculture.(health hazards ,pneumoconiasis) SU 6.1, 6.2. surgical infections: etiology an Prophylactic and therapeutic a			OG 7.1 MATERNAL CHANGES IN PREGNANCY(L)	lunch break	Bioethics - Case	ccom Module 2.5 e studies on patient autonomy n makingioethics contd 2L	SPORTS	
19-06-2022	SUN	8 TO 9	11 to 12	12 to 1 PM						

20-06-2022	MON	CLINICAL POSTING			Drugs used in bronchial asthma and COPD PH1.32 (L) PA 21.4 (L) Define and	Drugs used in bronchial asthma and COPD PH1.32 (SGD) INTEGRATED WITH RESPIRATORY MEDICINE	1 - 2	PA 21.1 ,21.3 (L) Describe normal hemostasis (core) PA 21.3 Differentiate Platelet from Clotting disorders based on clinical	PA 21.2 SGD Classify and Describe the etiology, pathogenesis and pathology of vascular and platelet disorders including ITP and hemophilia (core)
21-06-2022	TUE	CLINICAL POSTING			describe Disseminated Intravascular Coagulation, its Laboratory findings and diagnosis of DIC (core)				General Microbiology & Immunology
22-06-2022	WED		SDL - SYMPOSIUM Parasitic infections Leishmaniasis, (Kala azar and Cutaneous), Cutaneous larva migrans, subcutaneous tissue nematodes, Filariasis MI 4.2, 4.3, 8.13, 8.15	SDL - SYMPOSIUM Fungal infections Superficial and subcutaneous mycoses Penicillium marneffei, Cutaneous manifestations of Systemic mycosis MI 4.2, 4.3, 8.13, 8.15		Describe the mechanisms of action, types, dosses, side effect of sex hormones PH1. 37(SGD)	Describe the mechanisms of action, types, doses, side effect of sex hormones PH1.37(SGD)		
23-06-2022	THU	CLINICAL POSTING CLINICAL POSTING			L Infective Syndromes of RT & Streptococcal pharyngitis MI 6.1	Describe MOA,uses,a/e of uterine relaxantsPH1. 41(SGD)		PA 21.5 SGD Define and describe Disseminated Intravascular Coagulation, its Laboratory findings and diagnosis of Vitamin K deficiency (core)	C M 11.3 Enumerate and describe specific occupational health hazards,their risk factors, preventive measures.
24-06-2022	FRI	CLINICAL POSTING			PA 20.1 (L) Describe the features of plasma cell myeloma	lunch break		Describe drugs used for infertility &erectile dysfunctionPH1.40(SGD)	FM 2.22,2.23(L) - AUTOPSY DEMONSTARTION- MECHANICAL ASPHYXIA
25-06-2022	SAT	FM 2.25 (SGD) - THERMAL DEATH	14.1, 14.2, 14.3. sterilization and disinfection. surgical approaches, incisions & instruments in general surgery.		OG 8.6 NUTRITION IN PREGNANCY-COUNSEL (DOAP)	lunch break	Bioe	aetcom Module 2.6 ethics contd 2 SGD	SPORTS
26-06-2022	SUN	8 TO 9	9 to 10	10 -to 11	11 to 12	12 to 1 PM			
27-06-2022	MON	CLINICAL POSTING			Describe MOA,uses,a,e of drugs used in diabetes PH1. 36(L)	Describe MOA,uses,a,e of drugs used in diabetes PH1.36(L)	1 - 2	PA 22 (SGD) Blood banking and transfusion	
28-06-2022	TUE				PA23.2 (SGD) Describe abnormal findings in body fluids in various disease states	PA34.1 - 3 (L) SKIN		infectiv	1L and 1 SGD ve syndromes of Skin,Soft tissue and Musculskeletal system MI 4.1, 4.2, 4.3 and Staphylococcal infections MI 1.2
		CLINICAL POSTING							

29-06-2022	WED	CLINICAL POSTING			L Infective Syndromes of RT & Streptococcal pharyngitis MI 6.1	1 L Diphtheria, Pertussis MI 6.1, 6.2	Describe mechanism of action, classes, side effects, indications and contraindications of antidiabetic drugs PH1.36(L) - Integrated (General Medicine)	Describe mechanism of action, classes, side effects, indications and contraindications of antidiabetic drugs PH1.36(L) - Integrated (General Medicine)
30-06-2022	THU	CLINICAL POSTING			1 L RTI due to Pseudomonas, Acinetobacter, Burkholderia & Others MI 6.1, 6.3, 4.3	Describe MOA,uses,a,e of drugs used in thyroid disorders PH1.36(L)	PA33.1 - 2 (L) OSTEOMYELITIS AND BONE TUMOURS	CM11.2 Describe the role, benefits and functioning of the ESI scheme CM 11.4 Describe the principles of ergonomics in health preservation
01-07-2022	FRI	CLINICAL POSTING			PA33.1 - 2 (L) OSTEOMYELITIS AND BONE TUMOURS	lunch break	Describe MOA,uses,a,e of drug used in osteoporosis PH1.36(SGD)	FM 2.26 (SGD /AUTOPSY DEMONSTRATION)- INJURIES DUE TO PHYSICAL AGENTS 1
02-07-2022	SAT	CM 20.2 Describe various issues during outbreaks and their prevention in the context of covid-19	SU9.1 endoscopy	Define, discuss, describe&distinguish community accquired pneumonia, no so comial pneumonia&aspirtation	OG 9.4 GTN, OG 9.5 HEG(L)	lunch break	aetcom thics continued – Case studies onomy and decision making SDL 2	SPORTS
03-07-2022	SUN							
04-07-2022	MON	CLINICAL POSTING			es,a/e of General anaesthetic	s PH1.18 (L) - Integrated (PA 33.3- SGD- Soft tissue tumours
05-07-2022	TUE	CLINICAL POSTING			PA 33.4- SDL PAGETS DISEASE	PA 33.5- SDL RHEUMATOID ARTHRITIS		1L + 1 SGD Tuberculosis & RI with NTM bacilli MI 6.1
06-07-2022	WED	CLINICAL POSTING			1L Bacterial Atypical pneumonia Mycoplasma, Chlamydia, Legionella & others MI 6.1 & 6.3	1 SDL & SGD Myxovirus infections of RT MI 6.1		Drugs used for contraception PH1.39(SGD)
07-07-2022	THU	CLINICAL POSTING			1L COVID 19 & other Corona virus MI 6.1	ibe MOA,uses,a/e of corti	PA 26.1 ,26.2- (L) RESPIRATORY SYSTEM - Pneumonia, Lung abscess	CM 8.1 Prevention and control of Corona virus and other acute respiratory infections
08-07-2022	FRI	CLINICAL POSTING			PA 26.3- (L) RESPIRATORY SYSTEM- OAD		ribe MOA,uses,a/e of corticosb	FM 2.26 (SGD /AUTOPSY DEMONSTRATION)- INJURIES DUE TO PHYSICAL AGENTS 2

09-07-2022	SAT	FM 2.35 (SGD/AUTOPSY DEMO)-MAKING OPINION ANI SU 9.1, 9.2. early detection of cancer and multidisciplinary management. Breaking bad news in cancer treatment.	OG 10.1 APH(L)			2.5: Bioethics continued – Case ient autonomy and decision making (L)2hrs	SPORTS
10-07-2022	SUN						
11-07-2022	MON	CLINICAL POSTING	PH1.19 Describe MOA,uses,a Integrated (Physio				PA 2.8- (P) Cell injury
12-07-2022	TUE	CLINICAL POSTING CLINICAL POSTING	PA 26.5, 26.7- SGD RESPIRATORY SYSTEM- Occupational lung diseases, mesothelioma			Practical Demonstration - DOAP Gram Staining MI 8.15, 6.2, 6.3	
13-07-2022	WED	CLINICAL POSTING	1 Flipped class Miscellaneous Viral Infections of RT MI 6.1, 6.2	Feedback & Reflections SSTI & RTI (SGD)		r	PH2.1Demonstrate the understanding of various dosage form (SGD)
14-07-2022	THU	CLINICAL POSTING	1L CVS infections Infective Endocarditis, A/c Rheumatic fever & others MI 2.1, 2.2	Anterior pituitary hormones PH1.37 (SGD)		PA 26.3- (L) RESPIRATORY SYSTEM-OAD	CM 3.3Describe the actiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases
15-07-2022	FRI	CLINICAL POSTING	PA 26.4- (L) RESPIRATORY SYSTEM- TB INTEGRATED			PH1.19 Describe MOA,uses, a/e,CI of Opioids (L)	FM 3.3 , 3.4 (L / AUTOPSY) - MECHANICAL INJURIES 1
16-07-2022	SAT	CM 8.1 Discuss the epidemiologica l and control measures including the use of essential laboratory test at the primary care level for Small pox ,chicken pox	OG 11.1 MULTIPLE PREGNANCY(L)		Module 2.6	: Bioethics continued:	SPORTS
17-07-2022	SUN						
18-07-2022	MON	CLINICAL POSTING	PH1.19 Describe MOA,uses, a/e,Cl of antipsychotics (L)	PH1.19 Describe MOA, uses,a/e,Cl of antipsychotics (SGD)			PA 3.2- (P) AMYLOIDOSIS
19-07-2022	TUE	CLINICAL POSTING		PA 27.1- (L)- CVS- ARTERIOSCLEROSIS			1 L, 1 SGD Enteric Fever - S.Typhi & S.Paratyphi MI 3.3
20-07-2022	WED	CLINICAL POSTING	1 L Leptospirosis MI 8.1	1 SGD Brucellosis, Borreliosis MI 8.1			PH2.2 Prepare ORS and explain its use (SGD)

21-07-2022	THU	CLINICAL POSTING	1L Rickettsial infections MI 1.1	PH1.19 Sedatives& hypnotics (SGD)	PA 27.4- (L)- CVS RHEUMATIC FEVE INTEGRATED WITH MII 12.3	R
22-07-2022	FRI	CLINICAL POSTING	PA 27.6, 27.7- (L)- CVS- INFECTIVE ENDOCARDITIS, PERICARDITIS, PERICARDIAL EFFUSION		PH1.20 Alcohol St	FM 3.5,3.6 (L / AUTOPSY) - MECHANICAL INJURIES 2
23-07-2022	SAT	FM 3.7 (I/AUTOPSY)-INJURIES CONT,CERTIFICATION OF WOUND SU 6.3, 6.4, 6.5. Measures to reduce Surgical sil of the patient who classification of surgical wound presents with poisoning universal precautions. IM 21.1	OG12.1 HYPERTENSIVE DISORDERS OF PREG(L)		Aetcom Module 2.6: Bioethics continued studies on autonomy and decision makir 2)	
24-07-2022	SUN					
25-07-2022	MON	CLINICAL POSTING	PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anesthetics, and preanesthetic medications	PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anesthetics, and preanesthetic medications (SGD)		PA 4.4- (P)- ACUTE AND CHRONIC INFLAMMATION
26-07-2022	TUE	CLINICAL POSTING CLINICAL POSTING	PA 27.5- (L) CVS- ISCHE INTEGRATED V	MIC HEART DISEASE		1 SGD, 1 DOAP -SKILLS LAB Sepsis, CRBSI, IE, RHD Blood sample collection for culture MI 8.15, 2.3
27-07-2022	WED	CLINICAL POSTING	1L Blood stream infections causing anaemia MI 2.1, 2.2,	1L Malaria & Babesiosis MI 2.5, 8.16 INTEGRATED	PH1.22 Desc	ibe drugs of abuse & PH1.23 Describe mechanism of deaddiction (SGD) INTEGRATED WITH PSY
28-07-2022	THU	CLINICAL POSTING	1L KALA AZAR Trypanosomiasis, & other parasitic MI 2.5, 8.16	PH1.52 Describe pharmacotherapy of poisoning (L) -Integrated (General Medicine)	PA 27.2, 27.3- (SGD) ANEURYSM, HEART F/	
29-07-2022	FRI	CLINICAL POSTING	PA 27.9, 27.10- (SGD) CVS- CARDIOMYOPATHY, SYPHILIS		PH1-17 Describe the mechanis action, types, doses, effects, indications of contraindications of anesthetics (L)	side and
30-07-2022	SAT	CM 8.1 Epidemiology &Control of Leptospirosis Discuss and describe epidemiology, antecedents and risk factors for atherosclerosis and IHD IM 2.1.Discuss the aetiology of risk factors both modifiable and non modifiable of atherosclerosis and IHD IM 2.1.Discuss and IHD IM 2.1			Aetcom module Module 2.6: Bioeth continued: Case studies on autonomy decision making SGD/L	
31-07-2022	SUN					

				PH1.19 Antidepressants			PA 6.7- (P) HEMODYNAMIC DISORDERS
01 00 2022	MON						
01-08-2022	MON		PH1.19 Antidepressants (L)				
		CLINICAL POSTING	DAGC 1 (SCD) EVE	DA 24 2 24 2 (SCD) CIT			1L & 1 Practicals
			PA36.1- (SGD)- EYE	PA 24.2, 24.3- (SGD) GIT- PEPTIC ULCER DISEASE			Filariasis & Demonstration of haematoparasites
02-08-2022	TUE						MI 2.5, 8.16
		CLINICAL POSTING					
			1L HIV	1L HIV		PH2.3 Demor	nstrate the appropriate setting up of an IV drip in a simulated environment (DOAP)
03-08-2022	WED		MI 2.7	MI 2.7			
		CLINICAL POSTING		INTEGRATED (Medicine)			
			1L	PH1.19 Drugs in bipolar			
04-08-2022	THU		VHF Dengue, CHIK, KFD	disorders & anxiety (L)		PA 24.4 (L) GIT- CA STOMACH	CM 8.1 Discuss the epidemiology and control measures of Dengue, CHIK, KFD
04 00 2022	1110		& others			TAZ4.4 (E) GIT CA STOWACT	measures of Bengue, Critic, Kr B
		CLINICAL POSTING	PA 24.7 (L) GIT- CA COLON			PH1.19 Drugs for	FM 3.9(SGD)- FIREARM INJURIES 1
						neurodegenerative diseases	
05-08-2022	FRI					(SGD)	
		CLINICAL POSTING	00.40.5.155.01				0.000
			OG 12.5 UTI IN PREGNANCY, OG 12.6 LIVER		Aetcom Module 2.7: Bioethics		SPORTS
06-08-2022	CAT		DISEASES IN PREG(L)		continued: Case		
06-08-2022	SAT	10.1, 10.2			studies on autonomy and		
		Principles of peri operative ma Informed consent Describe and discuss the ac			decision making (L) 1hrs	Aetcom Module 2.7: Bioethics	
		milorined consent. Describe and discuss the ac			(L) IIIIS	Aetcom Module 2.7. Bioethics	
07-08-2022	SUN						
07 00 2022	5011						
				PH1.19			PA 24.1- (SGD) -GIT- ORAL CANCERS AND SALIVARY GLAND TUMORS
08-08-2022	MON						
08-08-2022	MON						
		CLINICAL POSTING	Antiepileptics (L) PA 24.5,24.6- (SGD/SYMP	OSIA) CIT IBD AND TB			1 SGD + 1 Practicals
			PA 24.5,24.0- (3GD/31WP	OSIA) GIT- IBD AND TB			Systemic Mycosis & Demonstration of Viral diagnostic tests
09-08-2022	TUE						MI 8.15, 2.7
		CLINICAL POSTING					
			1L Gastrointestinal Infective Syndrome and Shigella MI	1SGD Food Poisoisoning: S.aureus, Bacillus cereus,		PH3.1 Write a r	ational and correct legible generic prescription and communicate to the patient SGD
10-08-2022	WED		3.1	Clostridium botulinum			
		CLINICAL POSTING		and others MI 3.5			
			1SDL and 1L Diarrhoegenic E.coli, NTS and yersiniosis,	PH1.16 Describe MOA, types,			
			Cholera, halophilic Vibrio			PA 25.1, 25.2-	
11-08-2022	THU		and Aeromonas InfectionsMI 3.1	and contraindications of the drugs modulating		HEPATOBILIARY SYSTEM (L)-	CM 8.1 Describe the principles and enumerate the measures to control an outbreak of food poisoning.
11-00-2022	1110		mectionsivii 3.1			JAUNDICE; HEPATIC FAILURE INTEGRATED WITH IM 5.4,6	measures to control an outsteak of food poisoning.
				histaminics, 5-HT modulating drugs,		WITT IN 5.4,0	
		CLINICAL POSTING		NSAIDs (L)			

12-08-2022	FRI	CLINICAL POSTING			PA 25.4, 24.5- HEPATOBILIARY SYSTEM (L)- CIRRHOSIS, PORTAL HYPERTENSION			PH1.16 Describe MOA, types, doses, s/e, indications and contraindications of the drugs modulating autacoids - anti-histaminics, 5-HT modulating drugs, NSAIDs (L)	FM 3.10 (L) - FIREARM INJURIES
13-08-2022	SAT	CM 8.1 Epidemiology &control of Cholera			OG 12.7 HIV IN PREGNANCY (L)		Aetcom Module 2.7: Bioethics continued: Case studies on autonomy and decision making(SGD) 2hrs		Aetcom Module 2.7: Bioethics continued: Case studies on autonomy and decision making(L) 1hr
14-08-2022	SUN	n							
15-08-2022	MON	CLINICAL POSTING			PH1.16 Anti-rheumatoid, anti gout drugs, management ogf migraine (SGD)	PH1.16 Anti-rheumatoid, anti gout drugs, management ogf migraine (SGD)			PA 8.3- (P) CYTOLOGY
16-08-2022	TUE	CLINICAL POSTING			PA 28.1- 28.5- (L) URINARY GLOMERULO	TRACT- RENAL FAILURE, NEPHRITIS		SGD/Practical: Stool microsc	opy, Staining, Intestrinal Protozoans, Giardiasis, Coccidian Parasitic Infections, blastocystosis and othersMI 1.2, 3.1,3.2
17-08-2022	WED	CLINICAL POSTING			1 SGD &SDL Miscellaneous Bacterial Infections of gastrointestinal System: Helicobacter, Campylobacter and Clostridium difficile Infections, Viral gastroenteritis (Rotaviruses and others)MI 3.6& MI3.1	1L Intestinal Protozoan Infections: Amoebiasis and balantidiasis MI3.1		PH3.1 Write a ra	ational and correct legible generic prescription and communicate to the patient SGD
18-08-2022	THU	CLINICAL POSTING CLINICAL POSTING			1L Intestinal Cestodes and Trematodes MI3.1	PH1.24 Drugs affecting renal systems including diuretics, antidiuretics-vasopressin and analogues (L)		PA 28.6 ,28.8, 28.9- (L) URINARY TRACT- IgA nephropathy, Tubulo interstitial diseases	CM 8.1 Describe the principles and enumerate themeasures to control intestinal parasitic infections .
19-08-2022	FRI	CLINICAL POSTING			PA 28.12- (L) URINARY TRACT- CYSTIC RENAL DISEASES			PH2.4 Demonstrate the correct method of dosage calculation in special situtions (SGD)	FM 3.11(SGD/AUTOPSY)- REGIONAL INJURIES 1
20-08-2022	SAT	CM 8.1 Discuss the control measures of Acute diarrhoeal diseases in the Community	SU 10.3 Emergency lifesaving surgical procedures.	OG16.1 PPH(L)	IM5.6 Pathophysiology, clinical evolution and complications of cirrhosis and portal hypertension			Aetcom Module 2.8 an to be a family member of a ospital visit and interaction)	SPORTS
21-08-2022	SUN								
22-08-2022	MON	CLINICAL POSTING			PH1.24 Drugs affecting renal systems including diuretics, antidiuretics - vasopressin and analogues (SGD)	PH1.25 Anticoagulants (L)		PA	x 13.5- (P) - Peripheral smear preperation and interpretation in anemia
23-08-2022	TUE	CLINICAL POSTING			PA 28.12 SYMPOSIA RE	NAL CYSTIC DISEASES		P/SGI	O -Protozoans: Nematodes, Trematodes, Cestodes and others MI 3.1,3.2

					1L Intestinal Nematode Infections: Trichuris,	1L infective syndromes of			PH4.1 Administer drugs through various routes DOAP
24-08-2022	WED				Enterobius, hookworm,	hepatobiliary system			
24-08-2022	WED				Strongyloides, Ascaris and	Viral hepatitis			
					others MI 3.1	Introduction			
		CLINICAL POSTING				MI 3.7 (ALIGNED)			
					1L Viral Hepatitis	PH1.25 Antiplatelets (L)		PA 28.14- 28.16- (L) URINARY	CM 8.1 Describe the principles and enumerate themeasures to control intestinal parasitic
25-08-2022	THU				Yellow Fever & others			TRACT- RENAL TUMOURS,	infections .
					MI 3.7 (ALIGNED)			UROTHELIAL TUMOURS	
		CLINICAL POSTING							
					PA 25.3- HEPATOBILIARY SYSTEM (SGD)- HEPATITIS			PH1.25 Fibrinilytics & plasma	FM 3.11(SGD/AUTOPSY)- REGIONAL INJURIES 2
26-08-2022	FRI				INTEGRATED WITH MI 3.7			expanders (SGD)	
20 00 2022					AND IM 5.12, 6				
		CLINICAL POSTING							
		CM 8.1 Epidemiology and control of Viral Hepatitis	SU 10.1,	Epidemiology,	OG 17.1 PHYSIOLOGY OF			com Module 2.8: What does it	SPORTS
27-08-2022	SAT	(ALIGNED)	Perioperative care.	microbiology,immunology	BREAST FEEDING(L)(mean to be fam	ily member of a sick patient?	
27-08-2022	SAI			and clinical evolution of viral hepatitisIM 5.4	BREAST FEEDING(L)(
				Viral riepatitistivi 5.4					
			•						
20 00 2022	arn.								
28-08-2022	SUN								
					PH1.26 Drugs mod	dulating RAAS(L)			PA 14.3- (P)- PS IN MHA
29-08-2022	MON								
		CLINICAL POSTING							
		CERTETOSTINO			PA 28.7, 28.15- (SGD) URI	NARY TRACT- DIABETIC			1 SGD + 1 Practical
					NEPHROPATHY, MYELOMA	A KIDNEY, THROMBOTIC			Parasitic infections of Hepatobiliary system
30-08-2022	TUE				ANGIOPA	ATHIES		Amoebic Liv	rer abscess, Hydatid disease, Fasciola hepatica, Clonorchis, Opisthorchis & others
		CLINICAL POSTING							MI 3.1, 1.1
		CERTETOSTITO			1 SGD	L1			PH4.1 Administer drugs through various routes (DOAP)
					Ocular & Ear infections	Infective syndromes of			
31-08-2022	WED				MI 1.1	CNS			
		CUDICAL POSTNIC				Meningitis & Encephalitis			
		CLINICAL POSTING			1L	MI 5.1, 5.2 PH1.26 Antihypertensive			
					10	drugs and			
					Acute bacterial Meningitis	drugs used in shock (L)			
01-09-2022	THU				(Pyogenic)			PA 35.1, 35.2- (L)- CNS-	CM 8.1 Epidemiology and prevention of bacterial meningitis
					N.meningitidis, Pneumococci, Hib			MENINGITIS AND TUMOURS	
					GBS, Listeria, E.coli &				
		CLINICAL POSTING			Others MI 5.1				
					PA 28.13- (SGD) - URINARY			PH1.26 Antihypertensive	FM 3.20(SGD) - DISPUTED PATERNITY AND MATERNITY
02 00 2025	FD.				TRACT- OBSTRUCTIVE			drugs and	
02-09-2022	FRI				UROPATHY			drugs used in shock (SGD)	
		CLINICAL POSTING							
		FM 8.1,8.2 (SDL) - INTRODUCTION TO TOXICOLOGY	SU 10.3	OG 19.1 PUERPERIUM	IM10.1 Define,describe and				SPORTS
			Principles of post operative		diffrentiate between acute				
02 00 2022	CAT		care for minor surgical	COUNSELLING FOR	and chronic renal failure				
03-09-2022	SAT		procedures.	CONTRACEPTION & PPS(L)	pathophysiology and causes		Module 2.8: V	What does it mean to be	
					of pre renal, renal and post			er of a sick patient? GD	
					renal ARF		2 hrs		
.									
	1								

04-09-2022	SUN									
									PA 14.3- (P)- PS IN MACROCYTIC ANEMIA	
05-09-2022	MON									
		CLINICAL POSTING			PH1.28 Drugs used inisch PA 28.10- (SGD) URINARY				1 SGD.	
					PA 28.10- (3GD) UNINANT	TRACI- PTELONEPHRITIS		Chronic Bacterial meningitis9Tubercular,Spirochaetal, Lyme disease etc)		
06-09-2022	TUE							tyme disease etc) 1 practical Agents of Pyogenic meningitis (N.meningitidis, S.pneumoniae, H.influenzae) & Agents of Neonatal meningitis- E coli, GBS.		
		CUBICAL POSTNIC						Agents of Pyogenic meningi	itis (N.meningitiois, S.pneumoniae, H.influenzae) & Agents of Neonatal meningitis- E coil, GBS. MI 5.3	
		CLINICAL POSTING	1L	1 L		PH5	5.1 Communicate with patient with ethics & empathy - exercises (SGD)			
			Poliomyelitis & Other agents of Viral Meningitis	Viral Encephalitis Rabies, HSV						
07-09-2022	WED				(Coxsackievirus) MI 5.1 , 8.16	MI 5.2				
		CLINICAL POSTING								
					1L Encephalitis	PH1.29 Drugs used in congestive heart failure				
08-09-2022	THU				Arboviral (JE,WestNile, KFD) NIPAH, Slow Virus, PRIONS	(L)		PA 29.1-29.4- (L) MGS	CM 8.1Discuss the epidemiology and control measures including the use of essential laboratory test	
					MI 5.2 (ALIGNED)			(,,)	for RABIES	
		CLINICAL POSTING								
					PA 29.5- (SDL) MGS- PROSTATITIS			PH1.29 Drugs used in congestive heart failure (L)	FM 8.3,8.4,8.5,8.6 (L/AUTOPSY) - GENERAL TOXICOLOGY 1	
09-09-2022	FRI									
		CLINICAL POSTING CM 8.1 Epidemiology and prevention of JE	SU 9.1.	Describe and discuss the	OG 22.1 PHYSIOLOGICAL		REFLECTION AND	LEARNING	SPORTS	
		&West Nile fever (ALIGNED)	investigations in surgical patients	response and influence of host immune status, risk						
10.00.2022	CAT			factors and comorbidities on zoonotic diseases and						
10-09-2022	SAT			nonfebrile infectious disease(tetanus) IM 25.1.						
				Common causes,						
				manifestations of these						
11-09-2022	SUN									
11 07-2022	5514									
					PH3.2 Prescripti	ion audit SGD			PA 14.3- (P)- PS IN hemolytic anemia	
12-09-2022	MON									
		CLINICAL POSTING								
					PA 30.7, 30.8-(SGD) - F adenom				1 SGD , 1 practicals Lab Diagnosis of Pyogenic meningitis & Cryptococcal Meningitis	
13-09-2022	TUE								(Choose & Interpret the laboratory Report) MI 5.3, 8.15	
		CLINICAL POSTING								

14-09-2022	WED	CLINICAL POSTING	1SGD Parasitic CNS Infections Neurocysticercosis, Free Living Amoebe, Toxoplasmosis & Other MI 5.1, 5.2	1 SGD Fungal CNS infections Cryptococcal & Others MI 5.1, 5.2		PH3.2 Prescription audit SGD			
15-09-2022	THU	CLINICAL POSTING	1L Tetanus & Botulism MI 4.1	PH1.30 Antiarrhythmics (L)		PA 30.2 ,30.9 (L) - FGS- CA ENDOMETRIUM	CM 8.1 Epidemiology &prevention of Tetanus and Trachoma		
16-09-2022	FRI	CLINICAL POSTING	PA 30.1, 30.3 -(L) - FGS- CA CERVIX, SMOOTH MUSCLE TUMOURS OF UTERUS			PH1.31 Drugs used in management of dyslipidemias (SGD)	FM 8.7,8.8,8.9,8.10 (L/AUTOPSY) - GENERAL TOXICOLOGY 2		
17-09-2022	SAT	FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY1	OG 23.1 NORMAL & ABNORMAL PUBERTY, OG 23.2 DELAYED PUBERTY, OG 23.3 PRECOCIOUS PUBERTY		AETCOM	-Formative assessment SPORTS			
18-09-2022	SUN								
19-09-2022	MON	CLINICAL POSTING	PH3.3 Critical evaluation of drug promotional literature SGD				PA 19.3- (P) TB LYMPHNODE		
20-09-2022	TUE	CLINICAL POSTING	PA 30.5 -(SGD) - FGS- GESTATIONAL TROPHOBLASTIC DISEASES			Urinary Tract Infection - Int	1L roduction and overview on various pathogens and infective syndroms of Urinary tract (E.coli) M17.3 1 SGD Lab. diagnosis Of UTI		
21-09-2022	WED	CLINICAL POSTING	1 SGD Klebsiella, Psudomonas, Proteus Staph.saprophyticus & Others & CAUTI MI 7.3	1 SGD TB Nephritis MI 7.3		PH3.3 Critical evaluation of drug promotional literature (SGD)			
22-09-2022	THU	CLINICAL POSTING	1 L Infective Syndromes of Genital Tract Syphilis MI 7.1, 7.2	PH1.35 Drugs used in hematological disorders (SGD)		FORMATIVE ASESSMENT	CM 8.1 Epidemiology and prevention of Sexually transmitted infections		
23-09-2022	FRI	CLINICAL POSTING CLINICAL POSTING	FORMATIVE ASSESSMENT			PH1.34 Drugs used in acid peptic desease (L)	FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY2		
24-09-2022	SAT	Community Medicine -Internal Assessment I	OG 24.1N AUB(L)		AETCOM - COMN CARE	MUNICATION AND PATIENT	SPORTS		
25-09-2022	SUN								

			PH3.5 To prepare and expl				FORMATIVE ASESSMENT
26-09-2022	MON		case (S	GGD)			
		CLINICAL POSTING					
		CELICIE I SOLLIO	PA 30.4-(L) - FGS- OVARIAN TUMOURS	PA 30.6-(SDL) - FGS- CERVICITIS			1 SGD, 1 Practical Lab Diagnosis of UTI
27-09-2022	TUE		TOMOURS	CERVICITIS		9	Sample collection, Transport, Lab Processing, Interpretation of report
		CLINICAL POSTING					MI 7.3 , 8.15
			SDL + 1 SGD Gonorrhoea & NGU	1 L Lab diagnosis of STI			PH3.5 To prepare and explain a list of P drugs for a case (SGD)
			MI 7.2	(Syphilis, Gonorrhoea, Trichomoniasis,			
28-09-2022	WED		(SDL- Bacterial vaginosis, Trichomoniasis, Vaginal	Candidiasis & others) MI 7.1, 7.2			
		CURING M. POSTRIA	Candidiasis)	WII 7.1, 7.2			
		CLINICAL POSTING	1 L	PH1.34 Antimetics (SGD)		PA 30.4 SGD /SYMPOSIA	
29-09-2022	THU		Ulcerative Genital diseases soft chancre, LGV, Genital			OVARIAN TUMOURS	CM 8.1Discuss the epidemiology and control
29-09-2022	1110		herpes, Granuloma inguinale etc				measures for Hepatitis B and C
		CLINICAL POSTING	MI 7.1, 7.2 PA 31.2- (L)- BREAST- CA			PH1.34 Antidiarrhoeals	
20.00.2022	EDI		BREAST				
30-09-2022	FRI					, IBD & IBS (SGD)	
		CLINICAL POSTING FM 9.2 (SGD) - CHEMICAL TOXICOLOGY Describe and discuss the					FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY3 SPORTS
		symptoms and signs of acute HIV seroconversion	28.3 OVU INDN, OG 30.1 PCOS(L)				
		IM 6.1.Define and classify HIV AIDS based on CDC					
01-10-2022	SAT	criteria IM 6.2.Describe and discuss the					
		relationship between CD4			antonio Madul	e 2.4 Working in health care	
		count and the risk of opporunistic infection IM			aetcom Modul	team	
02-10-2022	SUN						
							SYMPOSIUM FGS TOPICS COMBINED
03-10-2022	MON		PH3.4 Recognise and	report ADR (SGD)			
33 10 2022		CLINICAL POSTING	- The Cognise und				
			PA 31.2- (SGD)- BREAST- CA				2 SGD
04-10-2022	TUE		BREAST	GYNECOMASTIA			Opportunistic Infections Transplant infections, Immunocompromised
3. 10 2022	.01						MI 8.2Lab diagnosis of STI (Syphilis, Gonorrhoea, Trichomoniasis, Candidiasis & others)
		CLINICAL POSTING					MI 7.1, 7.2
			1 SGD	1 L			PH3.4 Recognise and report ADR (SGD)
05-10-2022	WED		Congenital Infections TORCHS, HIV, Hepatitis B,	Oncogenic Virus PAPOVA, Kaposi, HTLV,			
		CLINICAL POSTING	Zika & Others MI 1.1	EB Virus, HBV, HCV			

06-10-2022 07-10-2022	THU	CLINICAL POSTING			1 SDL + 1 SGD Zoonotic infections Classification Plague, Tuleremia, Bite wound infections, NIPAH& Others MI 8.1 (ALIGNED) PA 32.1- (L)- ENDOCRINE- THYROID TUMOURS	PH1.34 Antidiarrhoeals, Laxatives, IBD & IBS (SGD)		PA 32.2, 32.3- (L)- ENDOCRINE- THYROIDITIS AND GRAVES PH1.50 immunomodulators and management of organ transplant rejection	CM 8.1Discuss the epidemiology and control measures of Plague FM 9.3 (SGD) - HEAVY METAL POISONING1
08-10-2022	SAT	CLINICAL POSTING CM 8.1Discuss the epidemiology and control measures of NIPAH virus infectionand Zika virus disease surgery. SU16.1. minimally invasive general surgery. OG31.1 UTERINE PROLAPSE(L)			IM 12.1 Epidemiology and pathogenesis of hypothyroidism and hyperthyroidism IM12.2 Describeand discuss the genetic basis of some thyroid dysfunction IM 12.3 Describe and discuss the physiology of hypothalamopitutary thyroid axis, principles of TFT and alterations in physiological functions		(SGD) AETCOM (MICROBIOLOGY COMPETENCY) Demonstrate Confidentiality pertaining to patient's identity MI 8.11, 8.12, 8.14 (1hr L and 1 SGD)		SPORTS
09-10-2022	SUN								
10-10-2022	MON	CLINICAL POSTING			PH1.52 management of cor poisoning, insecticides, cor sting and bites (SDL)	nmon			PA 19.5- (P)- LYMPH NODE- HODGKIN LYMPHOMA
11-10-2022	TUE	CLINICAL POSTING			PA 32.5- (SDL)- ENDOC	RINE- PARATHYROID			INTERNAL ASSESSMENT II
12-10-2022	WED	CLINICAL POSTING			1L Emerging & Re emerging Infections & A Agents of Bioterrorism MI 8.4	INTEGRATION With CM National Health programms for Communicable Diseases MI 8.16			INTERNAL ASSESSMENT II
13-10-2022	THU	CLINICAL POSTING			1 SGD Rational Use of Microbiological Investigations MI 8.13 AND REFLECTIONS	PH1.53 Describe heavy metal poisoning and chelating agents (SGD)		PA 32.4- (L)- ENDOCRINE- DIABETES	CM 8.1 IL Discuss the emerging and reemerging infections reported in the last decade and the public health mesures to combat it
14-10-2022	FRI	CLINICAL POSTING			PA 32.4- (L)- ENDOCRINE- DIABETES			PH1.54 Vaccines (SDL)	FM 9.3 (SGD) - HEAVY METAL POISONING2
15-10-2022	SAT				OG 32.1 MENOPAUSE & HRT(L)		for investigations	pect for patient's samples sent	SPORTS

16-10-2022	SUN									
17-10-2022	MON	CLINICAL POSTING			PH5.2 Motivate patients water to the prescribe				PA19.7- (P)- SPLENOMEGALY	
18-10-2022	TUE	CLINICAL POSTING			PA 32.7, 32.8- (SDL)- ENI ADRENAL INS			2 SGD Opportunistic Infections Transplant infections, infections in Immunocompromised MI 8.2		
19-10-2022	WED	CLINICAL POSTING			APPLIED MICROBIOLOGY Visit to CSSD MI 1.5 SGD	APPLIED MICROBIOLOGY Visit to Hospital BMW IMAGE MI 8.7 SGD		PH5.2 Communicate with	the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines SGD	
20-10-2022	THU	CLINICAL POSTING			1 SGD Antimicrobial Resistance & Relevance, Rational use of Antimicrobials MI 1.6	PH1.56 Describe basic aspects of Geriatric and Pediatric pharmacology SGD		PA 32.9- (L)- ENDOCRINE- ADRENAL TUMOURS	CM Essential and counterfeit medicines	
21-10-2022	FRI	CLINICAL POSTING			PA 32.6- (L)- ENDOCRINE- EXOCRINE PANCREAS			PH1.60 Pharmacogenomics and Pharmacoeconomicse (L)		
22-10-2022	SAT	CM Internal assesment II	SU 7.1, 7.2. surgical audit. Clinical research.	OG 33.1 CERVICAL CANCER/ PMLESIONS(L)	IM 22.1 Enumerate the causes of hypercalcemia and distinguish the features of PTH vs non PTH mediated hypercalcemia IM22.2Describe the etiology, clinical manifestations, diagnosis and clinical approach to primary		Demonstrate resp for	AETCOM OLOGY COMPETENCY) exect for patient's samples sent investigations, 1, 8.12, 8.14 (SGD)	SPORTS	
23-10-2022	SUN									
24-10-2022	MON	CLINICAL POSTING			PH1.57,1.58 drugs used in skin & ocular disorders (SGD)	PH1.57,1.58 drugs used in skin & ocular disorders (SGD)			PA 20.1- (P) MYELOMA	
25-10-2022	TUE	CLINICAL POSTING			FORMATIVE ASSESSME	NT AND REFLECTION			2 SGD Practicals Environmental Surveillance Bacteriology of Air, Water and Surface MI 8.81	
26-10-2022	WED	CLINICAL POSTING			INTEGRATION (L) Pandemic management MI	Pandemic management WITH CM (SGD)		PH5.2 Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines (SGD)	PH5.2 Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines (SGD)	
27-10-2022	THU	CLINICAL POSTING			Applied HIC ,MDR precautions and isolation SGD	PH1.61 dietary supplements and nutraceuticals (SDL)		SGD- GIT	CM -ATCOMModule 2.3: Health care as a right	

		T				DUA 60 11 11 1	F1 (0 4 (000) 4 (000) 0
				SGD- RESPIRATORY SYSTEM		PH1.62 antiseptics and disinfectants (SGD)	FM 9.4 (SGD)- ALCOHOL 2
28-10-2022	FRI					disinicctunts (505)	
		CLINICAL POSTING	01104.03	00344 AUD		DEFLECTION	
		FM 9.4 (SGD)- ALCOHOL 3	SU 8.1, 8.2. ethics in surgery.	OG24.1 AUB		REFLECTION	
29-10-2022	SAT		Professionalism & Empathy in				
			surgery				
30-10-2022	SUN						
					Pandemic management -		PA 23.1- (P)- URINE ANALYSIS
				Pandemic management -	Therapeutic strategies		FA 23.1" (F) ONINE ANALISIS
31-10-2022	MON			Therapeutic strategies including new drug	ncluding new drug		
31-10-2022	WON			development (Longitudinal	development		
		CLINICAL POSTING		Integration)	(Longitudinal Integration)		
		CLINICAL FOSTING		PA 23.3- (P)- SEMEN AN		Practicals - DOAP DONNING	G AND DOFFING ,APPROPRIATE USE OF PPE Demonstrate ICP Hand hygeine MI 8.7 DOAP
				, .	, ,	certific	
01-11-2022	TUE						
		CLINICAL POSTING					
				Choose the most	Choose the most		Pandemic management - Therapeutic strategies including new drug development (Longitudinal
				appopriate method of	appopriate method of		Integration)
02-11-2022	WED			sterilisation and	sterilisation and		
				disinfection to be used in specific clinical situations	disinfection to be used in specific surgical		
		CLINICAL POSTING		MI 1.5Practicals	practiseMI 1.5Practicals	ding new drug development (Lo	
				BIOMEDICAL WASTE	Pandemic management -		
				DISPOSAL - SGD 1	Therapeutic strategies		
03-11-2022	THU				including new drug development	SGD- MGS	CM 6.1 Designing a research proposal
					(Longitudinal		
		CLINICAL POSTING			Integration)		
		T					
				SGD- FGS		Pandemic management - Therapeutic strategies	FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS1
04-11-2022	FRI					including new drug	
						development (Longitudinal	
		CLINICAL POSTING		00004 2554445		Integration)	
		CM 6.1 Developing a proposal -Literature search		OG28.1.2FEMALE INFERTILITY		FORMATIVE assessment	
05-11-2022	SAT						
06-11-2022	SUN						
					PH5.6 Demonstrate		PA 25.6- (P)- HEPATITIS INTEGRATED
				DU4 50 5	ability to educate public		Treat (r) Hermino integrance
				PH1.59 Essential medicines, Fixed dose combinations,	& patients about various		
07-11-2022	MON			Over the counter drugs,	aspects of drug use		
				Herbal medicines (L)	including drug dependence and OTC		
		CLINICAL POSTING			drugs (SGD)		
		•					

08-11-2022	TUE		PA 27.8- (P)- CARDIAC FU CORONARY S			2SGD - Perform and Identii	y the causative agents of infectious diseases MI 1.2 (including candida species)MI DR7.2		
09-11-2022	WED	CLINICAL POSTING CLINICAL POSTING	Identify the etiology of meningitis based on given CSF parameters PA35.3 int with pathology	Identify the microbial agents causing meningitis (Int with IM and Pediatrics)MI5.3 DOAP		PHS	.7 Prepare a list of essential medicines for a healthcare facility (SGD)		
10-11-2022	THU	CLINICAL POSTING	choose the appropriate laboratory test in diagnosis of viral hepatitis with emphasis on viral markers MI3.8 SGD ,case discussion	PH1.63,1.64 drug development, clinical trials,GCP & ethical aspects (L)		SGD- ENODOCRINE	CM 6.1 Developing research proposal (Group work)		
11-11-2022	FRI	CLINICAL POSTING	SGD- BONE			PH5.7 Demonstrate an understanding of the legal and ethical aspects of prescribing drugs (SGD)	FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS2		
12-11-2022	SAT	FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS 3	OG 30.1.1PCOS			REFLECTION			
13-11-2022	SUN	·							
14-11-2022	MON	CLINICAL POSTING	PH4.2 Demonstrate the effects of drugs on BP (SGD)	PH4.2 Demonstrate the effects of drugs on BP (SGD)			PA 31.3- (P)- CA BREAST, FIBROADENOMA		
15-11-2022	TUE		PA 34.4- (P)- SKIN TUMOURS			SKILL LAB - Demonstrate the appropriate method of collection of samples in the performance of laboratory tests in detection of microbial agents (Blood collection, Swab from infected wound, Aspiration of specimens with ase			
16-11-2022	WED	CLINICAL POSTING CLINICAL POSTING	Identify the different modalities for diagnosis of enteric fever.choose the most appropriate test related to duration of illness MI3.4 SGD2			PH4.2 Demonstrate the effects of drugs on BP (SGD)	PH4.2 Demonstrate the effects of drugs on BP (SGD)		
17-11-2022	THU	CLINICAL POSTING CLINICAL POSTING	Identify the common aetiological agents of diarrhea and dysentry MI 3.2 SGD 1	PH3.6 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs (SGD)		SGD- SOFT TISSUE	Developing research proposal (Group work&Presentation)CM		
18-11-2022	FRI	CLINICAL POSTING	SGD- HEMATOLOGY			PH3.6 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs (SGD)	FM 9.6 (SGD)- RESPIRATORY POISONS1		
19-11-2022	SAT	CM Developing research proposal (Group work&Presentation) SU 5.4, 8.3. Medicolegal issues in surgical practice	OG29.1.1FIBROID UTERUS						
20-11-2022	SUN								

						PA 35.3- (P)- CSF EXAMINATION
21-11-2022	MON		REFLECTION			
		CLINICAL POSTING				
		CLINICAL POSTING	REFLECTION	SGD PERIPHERAL SMEAR		
22 11 2022	TOTAL TO			INTERPRETATION	Identify the causative	
22-11-2022	TUE				agent of Malaria and filariasis MI 2.6	
		CLINICAL POSTING			Practicals	
			Choose and interpret the results of the Laboratory	Choose and interpret reports of sputum,Blood		
23-11-2022	WED		tests used in UTI MI8.15	and other swabs MI 8.15		
		CLINICAL POSTING	SGD	SGD		
		CLINICAL POSTING	1 LTransfusion Transmitted			
24 11 2022	THE		Infections		SGD HEMOGLOBIN	D 1 ' 1/0 10D (/)
24-11-2022	THU				ESTIMATION	Developing research proposal (Group work&Presentation)
		CLINICAL POSTING				
			SGD ESR ESTIMATION			FM 9.6 (SGD)- RESPIRATORY POISONS 2
25-11-2022	FRI					
		CLINICAL POSTING				
		FM 14.7,14.8 (SGD/ SKILL) - BLOOD STAIN AND GROUPII SU 11.5.	OG 32.1.1MENOPAUSE			
26 11 2022	CAT	Day case & fast track surgery.				
26-11-2022	SAT					
27-11-2022	SUN					
						INTERNAL ASSESSMENT 3
28-11-2022	MON					
26-11-2022	MON					
		CLINICAL POSTING				HIERON ASSESSMENT OF
			FEEDBACK and Reflection			INTERNAL ASSESSMENT 3
29-11-2022	TUE					
		CLINICAL POSTING				
			choose the interpret approp	oriate diagnostic tests for		
30-11-2022	WED		diagnosis of HIV II integrated wit			
30-11-2022			integrated with	iii Wedicine		
		CLINICAL POSTING	FEEDBACK and Reflection			INTERNAL ASSESSMENT 3 CM Proposal presentation
			FEEDBACK and Reflection			Con Proposal presentation
01-12-2022	THU					
		CLINICAL POSTING				
			FEEDBACK and Reflection			FM 14.10 (SGD/ DOAP-SKILL)- INJURY INTERPRETATION
02-12-2022	FRI					
02 12 2022	110					
		CLINICAL POSTING	0622 1 1 8 22 1 2			
		CM 20.3 Describe any event important to health of the community . SU 11.6.	OG33.1.1 &33.1.2 PREMALIGNANTLESIONS OF			
03-12-2022	SAT		CERVIX&CA CERVIX			

					, , , , , , , , , , , , , , , , , , ,		
04-12-2022	SUN						
01 12 2022	SUN						